The Global Transdermal Drug Delivery Systems Market is Estimated to reach $72.4 Billion by 2028, at a CAGR of 4.6%
Special Offering :
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Transdermal Drug Delivery Systems Market Growth, Trends and Report Highlights
According to a new report, published by KBV research, The Global Transdermal Drug Delivery Systems Market size is expected to reach $72.4 billion by 2028, rising at a market growth of 4.6% CAGR during the forecast period.
The Analgesics market is generating high revenue in the Global Transdermal Drug Delivery Systems Market by Application in 2021; thereby, achieving a market value of $24.9 billion by 2028. The increasing prevalence of chronic pain and the expanding selection of transdermal pain relief medicines can be blamed for this segment's market growth. Analgesics are being used as a "pain relief patch."
The Active market would witness highest CAGR of 5.1% during (2022 - 2028). Many active innovations have already been turned into commercially successful products, and other platforms, like microneedles, are moving quickly in that direction. It may be advantageous to utilize microneedles that can actively push medications and macromolecules into the skin when quick delivery is required or to integrate micron-scale disturbance with an additional driving factor, such as iontophoresis.
The North America market dominated the Global Transdermal Drug Delivery Systems Market by Region in 2021; thereby, achieving a market value of $28.2 billion by 2028. The Europe market is experiencing a CAGR of 4.2% during (2022 - 2028). Additionally, The Asia Pacific market would witness a CAGR of 5.4% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/transdermal-drug-delivery-systems-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Viatris Inc., Bayer AG, Boehringer Ingelheim GmbH, Endo International plc, GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Purdue Pharma L.P., Altaris and Hisamitsu Pharmaceutical Co. Inc.
Global Transdermal Drug Delivery Systems Market Segmentation
By Application
- Analgesics
- Hormone Replacement Therapies
- Hypertension
- Motion Sickness
- Smoking Cessation
- Others
By Type of Delivery System
- Passive
- Active
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Companies Profiled
- Viatris Inc.
- Bayer AG
- Boehringer Ingelheim GmbH
- Endo International plc
- GlaxoSmithKline plc
- Johnson & Johnson
- Novartis AG
- Purdue Pharma L.P.
- Altaris
- Hisamitsu Pharmaceutical Co. Inc.
Related Reports:
North America Transdermal Drug Delivery Systems Market Size, 2028
- September-2022
- 68 Pages
LAMEA Transdermal Drug Delivery Systems Market Size, 2028
- September-2022
- 76 Pages
Europe Transdermal Drug Delivery Systems Market Size, 2028
- September-2022
- 76 Pages
Asia Pacific Transdermal Drug Delivery Systems Market Size, 2028
- September-2022
- 76 Pages